EPIPHANY study for people with moderate to severe asthma

The EPIPHANY study aims to identify the best treatments for people with moderate to severe asthma by using a new approach where each participant will be treated with guideline-based standard of care throughout the study and then evaluated by clinical responses and changes in expression of genes after treatment with FDA approved medications: systemic corticosteroid (triamcinolone acetonide), and two biologics for moderate to severe asthma an anti-IL-5 receptor (benralizumab) and anti-IL-4 receptor (dupilumab). Participation will include a screening and run-in period and if you qualify, 10 additional clinical visits. Study procedures include questionnaires, measurements, maintenance of a peak flow diary, blood draws, sputum (a mixture of saliva and mucus coughed up from the respiratory tract) collection, spirometry, fractional exhaled nitric oxide (FeNO) tests, and nasal brushings.

Eligibility:

• Male or female ages 18-65,
• Stable asthma medications, no changes in 2 months prior to screening,
• Use of high dose ICS and an additional controller medication,
• Baseline of poor or uncontrolled asthma,
• Bronchodilator reversibility/positive methacholine,
• Compliance to asthma medication and adherence to study protocol >80%.